Latest News

 Filter by Provider

Oklo trades at about $28 a share. Will it ever return to $190?

The cybersecurity specialist's stock has done well, but its business is lagging.

The shift to fixed-price contracts and proprietary tech is designed to expand margins without adding proportional headcount.

Is this the buying opportunity of the decade?

The real test is whether cost cuts and pricing gains can stick once steel demand normalizes.

This monthly dividend stock has a more than 30-year track record of annual dividend hikes.

Energy Transfer stock is hot, but history indicates that's not a reason to avoid it.

For the fifth consecutive Halloween, Rule Breaker Investing shares tales of financial terror.

While Ford is often praised for its lucrative dividend yield and additional "special dividends," General Motors actually has a total yield that is roughly double Ford's.

SpaceX reportedly wants to build a U.S. mobile network.

The insurer's new E&S growth engine and capital returns hinge on whether pricing discipline can sustain margin expansion as markets shift.

Debt reduction and share buybacks below asset value position the company to compound returns through the cycle.

Coupang's revenue runs 2.5x to 3x higher than Airbnb's, with minimal seasonal swings -- a stark contrast to Airbnb's predictable boom-bust cycle.

America’s most popular sport is in full swing, and what better time to ask whether the game we love could be even better?

Microsoft and Amazon have accelerated their cloud revenue thanks to AI spending.

NORMA Group (ETR:NOEJ) outlined its “New NORMA” strategy at its first capital markets day since the company’s 2011 initial public offering, setting targets for profitable growth, margin expansion and cash generation through 2031. Chief Executive Officer Birgit Seeger said the company is reorganizin

Even after removing the effect of one-time accounting benefits, one name remains at the bottom of the valuation pile.

If his 2030 projection for global data center capital expenditures pans out, the GPU giant could deliver multibagger returns from here.

The amount of the upcoming COLA will benefit retirees, but not as much as many of them need it to.

SK Hynix's revenue has surged to over $52 billion in the latest quarter, while Intel has remained relatively flat.

With such a long investment horizon, the choice is simple.

International deposits and deposit-cost discipline are reshaping the bank's margin profile as it clears legacy credit problems.

These leaders in cybersecurity, data analytics, and servers are benefiting from growth in AI spending.

The AI data analytics giant's third-quarter report provides a golden opportunity for it to show investors that its growth narrative is still strong.

Rapport Therapeutics (NASDAQ:RAPP) reported positive top-line results from a Phase II proof-of-concept trial of RAP-219 in adults with acute bipolar mania, meeting both its primary and secondary endpoints and supporting plans to advance the candidate into Phase III development. The three-week, plac

Walmart's new $120 bundled membership is a powerful move against Amazon's popular Prime.

IonQ and Nvidia are well-positioned to capitalize on two major computing build-outs.

Bear markets have historically provided some of the best buying opportunities.

Proprietary analytics and disciplined underwriting allow Kinsale to hold margins even as competitors cut prices in softening markets.

Before buying Space Exploration Technologies' stock, investors should understand why even a company built for the future could struggle to protect shareholders during a market downturn.

A Hess Midstream rebound demands investors' patience, but they'll harvest a 10% yield while they wait.

Newmont posted record Q3 adjusted earnings of $2.20 per share as gold held near a $4,000 floor, with improved cost guidance, strong free cash flow, buybacks, and dividends.

Odyssey Therapeutics (NASDAQ:ODTX) presented additional data from its open-label Phase IIa trial of OD-001, an oral RIPK2 scaffolding inhibitor for moderate-to-severe ulcerative colitis, during its UEG Week 2026 investor webcast. The company said the complete induction dataset, biomarker findings an

The leading space company just released another strong earnings report, but it still has some issues.

For many buy-and-hold investors just getting started, knowing how to understand businesses better is one of the first skills to develop. One term that the financial world has developed for business strengths is economic moat, which means something that keeps competitors from posing a real threat to a business.

Coca-Cola has had its best year since 1996.

Operating leverage from cost cuts is now compounding with margin expansion, a dual engine for earnings growth.

Multiyear renewal rates and AI-driven automation are expanding both customer stickiness and margin potential simultaneously.

The numbers paint a clear picture for shareholders.

Retirees in their 70s receive substantially more per month, but the gap reflects claiming patterns and lifetime earnings rather than automatic growth.

Management's pivot to commercial lending and fee income hinges on whether the bank can execute a balance sheet overhaul under new leadership.

Dow's $14 billion liquidity cushion through 2029 give it financial flexibility competitors may lack during uncertain cycles.

Mizuho upgraded Albemarle to Outperform with a $130 target, citing battery storage demand and low-cost production ahead of its Nov. 4 earnings report.

Things continue to get more exciting for Elon Musk's brainchild.

These funds each provide a different approach to inflation protection in your portfolio.

Aclara Resources (TSE:ARA) outlined plans to build an integrated rare-earth supply chain spanning two ionic-clay deposits in South America, a separation facility in Louisiana and a metals-and-alloys operation, with management emphasizing its focus on heavy rare earth elements including dysprosium, t

Micron is changing more toward contracts, rather than letting the open market dictate pricing.

If you're on Medicare, this is an opportunity you don't want to miss.

Royalty Pharma invests in a portfolio of drugs, from blockbusters to those still in development.

Coca-Cola, Monster Beverage, and Keurig Dr. Pepper have each gained at least 20% YTD as beverages lead a consumer staples rebound, with all three reporting Q3 2026 earnings soon.